Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)

American Journal of Cardiology

Volumn 104, Issue 10, 2009, Pages 1330-1335

  Linefsky, Jason P ^a   Lin, Min ^a   Pieper, Karen S ^a   Reist, Craig J ^a   Berdan, Lisa G ^a   Antman, Elliott M ^b   Goodman, Shaun G ^c   French, John K ^d   Guneri, Sema ^e   Roe, Matthew T ^a   Newby, L Kristin ^a   Harrington, Robert A ^a   Ferguson, James J ^f   Califf, Robert M ^a   Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f MEDICINES COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; ENOXAPARIN; HEPARIN;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL LABORATORY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; HUMANS; LABORATORIES; MYOCARDIAL INFARCTION;

EID: 71749118828     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.056     Document Type: Article

References (18)

1. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infraction. J Am Coll Cardiol 36 (2000) 959-969
2. SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 143 (2002) 952-960
3. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
4. Lin L.I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45 (1989) 255-268
5. Lin L.I. A note on the concordance correlation coefficient. Biometrics 56 (2000) 324-325
6. Wu A.H.B., Apple F.S., Gibler W.B., Jesse R.L., Warshaw M.M., and Valdes Jr. R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendation for the use of cardiac marker in coronary artery diseases. Clin Chem 45 (1999) 1104-1121
7. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339 (1999) 436-443
8. Christenson R.H., Vaidya H., Landt Y., Bauer R.S., Green S.F., Apple F.A., Jacob A., Magneson G.R., Nag S., Wu A.H., and Azzazy H.M. Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material. Clin Chem 45 (1999) 1414-1423
9. Panteghini M., and Pagani F. AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between 2 commercial immunoassays. Clin Chem 50 (2004) 1711-1712
10. Apple F.S. Clinical and analytical issues confronting cardiac troponin I. Clin Chem 45 (1999) 18-20
11. Panteghini M., Bunk D.M., Christenson R.H., Katrukha A., Porter R.A., Schimmel H., Wang L., Tate J.R., and IFCC Working Group on Standardization of Troponin. I. Standardization of troponin I measurements: an update. Clin Chem Lab Med 46 (2008) 1501-1506
12. Akkerhuis K.M., Deckers J.W., Boersma E., Harrington R.A., Stepinska J., Mahaffey K.W., Wilcox R.G., Lincoff A.M., Keltai M., Topol E.J., Califf R.M., and Simoons M.L. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Eur Heart J 21 (2000) 371-381
13. Apple F.S., Murakami M., Panteghini M., Christenson R.H., Dati F., Mair J., Wu A.H., and I.F.C.C. Committee on Standardization of Markers of Cardiac Damage. International survey on the use of cardiac markers. Clin Chem 47 (2001) 587-588
14. Lagakos S.W. The challenge of subgroup analyses: reporting without distorting. N Engl J Med 354 (2006) 1667-1669
15. Apple F.S., Jesse R.L., Newby K., Wu A.H.B., and Christenson R.H. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 115 (2007) e342-e355
16. Apple F.S., Quist H.E., Doyle P.J., Otto A.P., and Murakami M.M. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 49 (2003) 1331-1336
17. Guo Z., Wang Z., and Wang X. Studies on the stability of creatine kinase isozymes. Biochem Cell Biol 81 (2003) 9-16
18. Buttery J.E., Stuart S., and Pannall P.R. Stability of the CK-MB isoenzyme on routine storage. Clin Biochem 25 (1992) 11-13